F-1: Regentis Biomaterials Eyes Nasdaq Listing with $11.5 Million IPO

Regentis Biomaterials is seeking to raise capital through an initial public offering to fund the development and commercialization of its GelrinC cartilage repair product.

Summary

• Regentis Biomaterials Ltd., an Israeli regenerative medicine company, has filed for an initial public offering (IPO) to list its Ordinary Shares on the Nasdaq Capital Market under the symbol RGNT.
• The company aims to raise approximately $11.5 million through the offering of 909,090 Ordinary Shares, with an anticipated initial public offering price between $10.00 and $12.00 per share.
• The IPO is a firm commitment offering, and ThinkEquity is acting as the underwriter.
• Regentis plans to use the net proceeds primarily for the development and completion of its pivotal trial for GelrinC, a hydrogel implant for knee cartilage injuries, and preparation for PMA submission to the FDA.
• A portion of the proceeds will also be allocated to operations, research and development, EU marketing development, and repayment of existing loans.
• The company has granted the underwriter a 45-day option to purchase up to 136,364 additional Ordinary Shares to cover over-allotments.
• Regentis is currently conducting a pivotal trial for GelrinC in the United States and Europe, with 47 patients already treated.
• The company has applied for listing on the Nasdaq Capital Market, contingent on the Ordinary Shares being approved for listing.
• Prior to the closing of this offering, Regentis intends to complete a forward split of its outstanding Ordinary Shares at a ratio of 2.5-for-1.

Sentiment

Score: 6

Explanation: The document presents a mix of positive and negative factors. The company has a promising technology and has achieved some regulatory milestones, but it also faces significant financial challenges and competition. The sentiment is cautiously optimistic.

Positives

• GelrinC has already received CE mark approval in Europe, indicating some level of regulatory validation.
• The FDA has granted Regentis an IDE for its pivotal trial, suggesting a degree of confidence in the product's potential.
• The company has completed a pilot study with positive results, showing greater improvement and pain reduction compared to microfracture.
• The company has a strong intellectual property portfolio with 34 issued patents and 4 pending patent applications.
• The company has a clear plan for using the IPO proceeds, focusing on completing the pivotal trial and preparing for PMA submission.

Negatives

• The company has a limited operating history and has incurred significant operating losses since its inception.
• The company has not generated any revenue from product sales and may never be profitable.
• The company will need to raise substantial additional funding, which may not be available on acceptable terms, or at all.
• The company's financial statements contain an explanatory paragraph regarding substantial doubt about its ability to continue as a going concern.
• The company operates in a very competitive business environment.
• The company is dependent upon contract manufacturing organizations and raw material suppliers.
• The company's management team has limited experience managing a public company.

Risks

• Clinical trials may not be successful, and regulatory approval may not be granted.
• The company may face challenges in manufacturing, commercializing, and generating demand for GelrinC.
• The company may be unable to compete successfully against existing or potential competitors.
• The company is dependent on third parties to manage clinical studies and trials, perform related data collection and analysis, and to enroll patients for clinical trials.
• The company may be unable to generate sufficient cash to service all of its indebtedness.
• The market price of the company's Ordinary Shares may be volatile.
• The company may be a passive foreign investment company, or PFIC, for U.S. federal income tax purposes.
• Political, economic and military instability in the State of Israel may adversely affect the company's results of operations.

Future Outlook

The company expects to continue to incur significant and increasing operating losses for the foreseeable future as it continues to invest in research and development, clinical trials, and commercialization efforts.

Management Comments

• With GelrinC, we aim to bring to market a product for the therapy of an unmet need for the large market of cartilage injuries in the knee.
• We believe that our product offers a simple and economic procedure, which we believe will allow patients to recover quickly with potentially long-term outcomes.
• We aim to provide patients with safe, effective, simple, and lasting treatments that are cost effective.
• We believe that our Gelrin technology platform may also provide a solution to osteoarthritis and other cartilage injuries related to the ankle, wrist, and elbow.

Industry Context

The cartilage repair market is a large sector of orthopedic medicine, representing an estimated overall annual market opportunity of about 750,000 arthroscopic knee operations in the United States at a cost of $4 billion.

Comparison to Industry Standards

• The improvements observed in the Knee Injury and Osteoarthritis Outcome Score, or KOOS, and Virtual Analog Scale, or VAS, pain measurement scores taken over two years following the treatment were superior (100% greater improvement) to those seen with the traditional microfracture procedure, which is considered to be the current gold standard.
• Unlike microfracture surgery, treatment using GelrinC does not produce fibrous cartilage, but instead has been shown to grow hyalin cartilage, which is autologous to the natural cartilage of the patient.
• Current commercial therapies for cartilage repair involve the use of autologous cells harvested from the patients own healthy tissue, which has numerous disadvantages, including the need for expensive cell expansion facilities and the requirement for two surgical procedures.
• There is also another technology, CartiHeals (acquired by Smith & Nephew in January 2024) Agili-C, which was approved by the FDA in March 2022, that utilizes pre-formed implants that consist of a two layer plug, of which the lower layer is a mineral/coral material that has been shaped to be inserted into a hole drilled into bone, which part is expected to assimilate with the bone, and the upper layer part is a scaffold intended to serve as a growth host for the cartilage cells.

Legal Proceedings

• In 2019, a controversy has arisen between the Company and CSL Behring GmbH, or CSL, whether certain unshipped minimum purchase commitments for fibrinogen from 2018 to 2020 are to be paid by the Company pursuant to a Framework Supply Agreement dated March 8, 2016, or Framework Supply Agreement, by and between the Company and CSL, whereby CSL agreed to supply the Company with fibrinogen.

Related Party Transactions

• Between October 2024 and November 2024, we entered into bridge loan agreements, or the Bridge Loans, pursuant to which we obtained a bridge loan from the lenders thereto including certain related parties, including Dr. Ehud Geller, the chairman and a member of our board of directors, and Pini Ben Elazar, a director nominee.
• Between December 2023 and January 2024, we entered into loan agreements, or the 2024 Loan Agreements pursuant to which we obtained a loan in the aggregate amount of $150,000 from the lenders thereto including certain related parties including Dr. Ehud Geller, the chairman and a member of our board of directors and SCP Vitalife Partners (which is affiliated with our director, Jeff Dykan).
• On December 1, 2024, we entered into a loan agreement with our Chief Executive Officer, or the December 2024 Loan Agreement, according to which accrued payroll salary owed to him in the aggregate amount of $117,000 plus VAT was converted into a loan.

Stakeholder Impact

• Shareholders: Potential for increased value if GelrinC is successfully commercialized, but also risk of loss due to financial challenges and market competition.
• Employees: Potential for job growth and career opportunities if the company is successful, but also risk of job losses if the company fails.
• Patients: Potential for access to a new and effective treatment for knee cartilage injuries.
• Healthcare professionals: Potential for a new and cost-effective tool for treating cartilage injuries.

Next Steps

• Complete patient enrollment and required follow-up of the GelrinC pivotal trial.
• Apply for PMA marketing approval for GelrinC.
• Seek a strategic partner for marketing GelrinC in the United States.
• Look for a strategic partner for marketing GelrinC in Europe.
• Develop a pipeline of products for additional tissue regeneration opportunities.

Key Dates

Keywords

GelrinC, cartilage repair, regenerative medicine, IPO, biomaterials, orthopedic, FDA, hydrogel, clinical trial, PMA